Cvfg LLC Cuts Holdings in Eli Lilly and Company $LLY

Cvfg LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 14.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 3,829 shares of the company’s stock after selling 636 shares during the period. Eli Lilly and Company accounts for about 2.8% of Cvfg LLC’s investment portfolio, making the stock its 11th biggest holding. Cvfg LLC’s holdings in Eli Lilly and Company were worth $4,115,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Vestmark Advisory Solutions Inc. raised its stake in shares of Eli Lilly and Company by 92.4% during the 4th quarter. Vestmark Advisory Solutions Inc. now owns 33,762 shares of the company’s stock worth $36,283,000 after buying an additional 16,217 shares in the last quarter. Addison Advisors LLC raised its stake in shares of Eli Lilly and Company by 3.5% during the 4th quarter. Addison Advisors LLC now owns 1,380 shares of the company’s stock worth $1,483,000 after buying an additional 47 shares in the last quarter. Commonwealth Financial Services LLC raised its stake in shares of Eli Lilly and Company by 16.6% during the 4th quarter. Commonwealth Financial Services LLC now owns 1,037 shares of the company’s stock worth $1,114,000 after buying an additional 148 shares in the last quarter. Intellus Advisors LLC raised its stake in shares of Eli Lilly and Company by 76.1% during the 4th quarter. Intellus Advisors LLC now owns 13,145 shares of the company’s stock worth $14,127,000 after buying an additional 5,679 shares in the last quarter. Finally, Resolute Wealth Strategies LLC raised its stake in shares of Eli Lilly and Company by 8.9% during the 4th quarter. Resolute Wealth Strategies LLC now owns 1,596 shares of the company’s stock worth $1,715,000 after buying an additional 131 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide, Lilly’s next-generation obesity drug, delivered strong Phase 3 results, with patients losing up to 28.3% of body weight over 80 weeks and as much as 30.3% over 104 weeks in an extension study. The data strengthens the drug’s commercial outlook and supports expectations for a future regulatory filing. Article Title
• Positive Sentiment: The company said retatrutide produced “meaningful” weight loss and appears to be a potential blockbuster in the fast-growing obesity market, adding to momentum behind Lilly’s already-strong GLP-1 franchise. Article Title
• Positive Sentiment: Lilly also announced a broad oncology showcase for the 2026 ASCO meeting, including Phase 3 data for Retevmo and Verzenio, plus updates from its acquired Kelonia Therapeutics and other cancer programs. That highlights pipeline breadth beyond obesity and could support longer-term growth expectations. Article Title
• Positive Sentiment: Several commentary pieces also argued that Lilly’s booming GLP-1 and obesity portfolio, including Mounjaro, Zepbound and Foundayo, keeps its growth story intact and may leave the stock with more upside.
• Neutral Sentiment: Lilly completed the acquisition of Engage Biologics for up to $202 million, adding non-viral DNA delivery technology to its genetic medicine platform. The deal is strategically constructive, but likely too small to move earnings near term. Article Title
• Neutral Sentiment: Lilly also raised $8.9 billion in debt, which increases financial flexibility for pipeline expansion and acquisitions, though it adds leverage. Article Title
• Negative Sentiment: One legal headline noted a lawsuit alleging a Trulicity rebate fraud scheme that cost Lilly more than $200 million. While not the main driver today, it could create some overhang if litigation expands. Article Title

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on LLY shares. Berenberg Bank increased their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday, February 19th. Leerink Partners cut their target price on Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating for the company in a research note on Monday, April 27th. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Argus upped their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Finally, TD Cowen upped their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,219.26.

Eli Lilly and Company Stock Performance

LLY opened at $1,041.89 on Friday. The stock has a market cap of $981.19 billion, a P/E ratio of 37.01, a P/E/G ratio of 1.11 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock’s 50 day simple moving average is $941.52 and its 200 day simple moving average is $1,003.33. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.